Screener
4D Molecular Therapeutics FDMT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Accrued and other liabilities | (4,123) | (2,312) |
| Deferred revenue | 1,380 | (14) |
| Operating lease liabilities | (878) | (754) |
| Net cash used in operating activities | (68,125) | (47,758) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (33,519) | (134,077) |
| Maturities of marketable securities | 102,396 | 166,656 |
| Disposal (acquisition) of property and equipment | 11 | (631) |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's operating cash flow?
- 4D Molecular Therapeutics (FDMT) reported operating cash flow of -$68.13M in Q1 2026.
- How has 4D Molecular Therapeutics's operating cash flow changed year-over-year?
- 4D Molecular Therapeutics's operating cash flow decreased by 42.6% year-over-year, from -$47.76M to -$68.13M.
- What is the long-term trend for 4D Molecular Therapeutics's operating cash flow?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's operating cash flow has grown at a 24.9% compound annual growth rate (CAGR), from -$69.13M to -$134.59M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about 4D Molecular Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude